mannkind corp. Resources | BNET
On last.fm: Listen to Free Online Radio

BNET Industries

MannKind Corp. (MNKD) is in the Pharma Industry

Revenue
Dec 31 2007
$10.0K
Profit
Dec 31 2007
($293.1M)
Market Cap
Aug 27 2008
$319.0M

Latest News and Analysis

Additional Resources

  • MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008

    VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT. Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company...

    Articles 2008-08-04

  • BeaconEquity.com Issues Technical Trade Alerts on Market Movers: EXXI, IVAN, AXAS, MNKD, CYTK, SIRI

    DALLAS, July 31 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://beaconequity.com/m Today's Trade Alerts include: Energy XXI Ltd. , Ivanhoe Energy Inc. , Abraxas Petroleum...

    Articles 2008-07-31

  • MannKind to Present at Upcoming Conferences

    VALENCIA, Calif., June 16 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences. -- 18th Annual Wachovia Nantucket Equity Conference on Monday, June 23, ...

    Articles 2008-06-16

  • page 1 of 1
  • Incorporated: 1991
  • CEO: Mr. Alfred E. Mann
  • Employees: 609

MannKind is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. As of Dec 31 2006, Co.'s lead investigational product candidate is the Technosphere Insulin System, a dry powder therapy consisting of its proprietary Technosphere particles onto which insulin molecules are loaded. Co.'s Technosphere formulation technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. These loaded particles are then aerosolized and inhaled into the deep lung using Co.'s proprietary MedTone inhaler.

Key Competitors

advertisement
MannKind Corp. Company Info

Board of Directors

Mr. Alfred E. Mann

Chairman

Mr. Abraham E. Cohen

Mr. Hakan S. Edstrom

Ms. Heather Hay Murren

Mr. Ronald Consiglio

Dr. Michael A. Friedman M.D.

Mr. Kent Kresa

Mr. David H. MacCallum

Mr. Henry L. Nordhoff

Contact Information

28903 North Ave Paine

Valencia, CA

http://www.mannkindcorp.com

661 775-5300

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement